share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K:重大事件
美股SEC公告 ·  10/18 18:50

Moomoo AI 已提取核心訊息

On October 18, 2024, CVS Health Corporation announced a significant leadership change with the appointment of J. David Joyner as the new President and Chief Executive Officer, effective October 17, 2024. He succeeds Karen S. Lynch, who has stepped down from her role and resigned from the Board of Directors. Concurrently, Roger N. Farah has been appointed as Executive Chairman of the Board. Prior to his new role, Joyner served as the Executive Vice President and President of Pharmacy Services at CVS Health since January 2023 and has a long history with the company, including various executive roles. The announcement coincided with the release of preliminary third-quarter financial results for 2024, which included GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. The company...Show More
On October 18, 2024, CVS Health Corporation announced a significant leadership change with the appointment of J. David Joyner as the new President and Chief Executive Officer, effective October 17, 2024. He succeeds Karen S. Lynch, who has stepped down from her role and resigned from the Board of Directors. Concurrently, Roger N. Farah has been appointed as Executive Chairman of the Board. Prior to his new role, Joyner served as the Executive Vice President and President of Pharmacy Services at CVS Health since January 2023 and has a long history with the company, including various executive roles. The announcement coincided with the release of preliminary third-quarter financial results for 2024, which included GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. The company also disclosed charges related to premium deficiency reserves and a restructuring charge associated with store closures and cost reduction actions. Investors were advised that the previous guidance issued on August 7, 2024, should no longer be relied upon due to elevated medical cost pressures, and an update will be provided during the earnings call scheduled for November 6, 2024.
2024年10月18日,西維斯健康公司宣佈了重大的領導層變動,任命J. David Joyner爲新任總裁兼首席執行官,任職日期爲2024年10月17日。他接替了Karen S. Lynch,後者已經辭去了職務並從董事會辭職。同時,Roger N. Farah被任命爲董事會的執行主席。在擔任新角色之前,Joyner自2023年1月以來一直擔任西維斯健康公司的執行副總裁兼藥房服務總裁,並且在該公司擁有悠久的歷史,包括擔任過各種高管職務。這一消息與西維斯健康公司發佈2024年第三季度初步財務結果的同時公佈,其中包括攤薄後每股收益爲0.03至0.08美元,調整後每股收益爲1.05至1.10美元。該公司還披露了與溢價不足準備和與店鋪關閉以及成本削減措施相關的重組費用。投資者被告知,由於醫療成本壓力上升,不應再依賴於此前於2024年8月7日發佈的指引,關於醫療成本問題將在2024年11月6日安排的業績會上進行更新。
2024年10月18日,西維斯健康公司宣佈了重大的領導層變動,任命J. David Joyner爲新任總裁兼首席執行官,任職日期爲2024年10月17日。他接替了Karen S. Lynch,後者已經辭去了職務並從董事會辭職。同時,Roger N. Farah被任命爲董事會的執行主席。在擔任新角色之前,Joyner自2023年1月以來一直擔任西維斯健康公司的執行副總裁兼藥房服務總裁,並且在該公司擁有悠久的歷史,包括擔任過各種高管職務。這一消息與西維斯健康公司發佈2024年第三季度初步財務結果的同時公佈,其中包括攤薄後每股收益爲0.03至0.08美元,調整後每股收益爲1.05至1.10美元。該公司還披露了與溢價不足準備和與店鋪關閉以及成本削減措施相關的重組費用。投資者被告知,由於醫療成本壓力上升,不應再依賴於此前於2024年8月7日發佈的指引,關於醫療成本問題將在2024年11月6日安排的業績會上進行更新。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息